The U.S. Health Secretary just made a monumentally dangerous move that could potentially endanger the lives of millions. Health and Human Services Secretary (HHS) Robert F. Kennedy Jr. announced he is cancelling contracts and grants worth nearly $500 million earmarked to develop mRNA vaccines, as the long-time vaccine critic has repeatedly cast doubts about the safety and efficacy of shots, despite pushback from scientists.
mRNA vaccines represent a groundbreaking advancement in immunization technology, offering a faster, more adaptable, and highly effective approach to preventing infectious diseases. Unlike traditional vaccines that use weakened or inactivated pathogens, mRNA vaccines work by delivering a piece of genetic code (messenger RNA) into cells, instructing them to produce a harmless viral protein. This protein then triggers the immune system to mount a protective response without exposure to the actual virus. The rapid development and deployment of mRNA vaccines during the COVID-19 pandemic demonstrated their potential to quickly address emerging infectious threats, paving the way for vaccines against various diseases like influenza, Zika, and even some cancers.
READ: Gates Foundation pledges $2.5 billion towards women’s health initiatives (August 5, 2025)
In a statement Tuesday night, the Department of Health and Human Services described the move as a “coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA).”
The United States has been at the forefront of mRNA vaccine research and development, largely due to significant federal investment and collaboration with private industry and academia. Agencies such as the National Institutes of Health (NIH), Biomedical Advanced Research and Development Authority (BARDA), and the Department of Defense have provided crucial funding, infrastructure, and regulatory support. This federal backing accelerated the development of mRNA vaccines like Pfizer-BioNTech and Moderna’s COVID-19 vaccines, enabling emergency use authorization within a year of the virus’s discovery, an unprecedented timeline in vaccine history.
Moreover, the U.S. federal government continues to support mRNA technology through initiatives aimed at expanding its applications beyond COVID-19, including efforts to create universal flu vaccines, treatments for rare genetic diseases, and personalized cancer vaccines. Investment in mRNA manufacturing capacity, supply chains, and workforce training also reflects a commitment to maintaining global leadership in biotechnology innovation.
In a post on X, immunologist and former BARDA Director Rick Bright wrote: “BARDA invested in mRNA technology precisely because it could deliver safe, scalable vaccines in record time, a capability proven during COVID. By dismantling that platform, we’re crippling our front-line defense, just ahead of unknown biological threats.”
In 2021, Kennedy falsely claimed that the COVID-19 shots were “the deadliest vaccine ever made.”
The cancellation of the funding also risks slowing progress in developing new vaccines and therapies that rely on mRNA technology, which has shown promise beyond COVID-19. Without continued federal support, advancements in treatments for diseases like influenza, cancer, and rare genetic disorders may be delayed or halted.
The decision may also impact the U.S.’s ability to compete globally in biotechnology innovation, potentially ceding leadership to other countries investing heavily in mRNA research. In an era of evolving health threats, maintaining strong investment in cutting-edge vaccine technologies is crucial to safeguarding public health and ensuring rapid responses to future pandemics or biological crises.